Uptake on many biosimilars has been slow, in part because employers are often unsure about how to take appropriate action to encourage more – and more affordable – pharmaceutical options for employees and their dependents. Biosimilars in the Pharmacy Benefit search: National Alliance, Action Brief, Formulary
Menu
